宣泰医药：公司产品续约纳入国家医保目录

Core Viewpoint - The company announced that its product, Sitagliptin Metformin Extended-Release Tablets (II), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) through a national negotiation renewal [1] Group 1 - The inclusion of Sitagliptin Metformin Extended-Release Tablets (II) in the national drug list is a significant development for the company [1]